Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
SpringWorks Therapeutics has joined forces with UK major GlaxoSmithKline to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with GSK’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma. 27 June 2019
Biotechnology
The US Food and Drug Administration yesterday approved the first biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), and thus marking a third approved indication for Dupixent (dupilumab). 27 June 2019
Biotechnology
The precision gene therapy company Encoded Therapeutics has announced a $104 million Series C financing. 27 June 2019
Biotechnology
Privately-held UK biotech Immodulon has teamed up with Dutch firm myTomorrows to develop an Expanded Access Program (EAP) for the unlicensed drug IMM-101. 27 June 2019
Biotechnology
The US Centers for Disease Control and Prevention (CDC) has issued a new recommendation, supporting extended use of Gardasil 9 (human papillomavirus 9-valent vaccine). 27 June 2019
Biotechnology
Americans overwhelmingly support innovative gene therapies, which change the focus of medicine from treating illnesses to curing illnesses, according to a new poll from the California-based nonpartisan think tank, the Pacific Research Institute (PRI). 26 June 2019
Biotechnology
US gene therapy company Abeona Therapeutics has appointed Victor Paulus as senior vice president, regulatory affairs. 26 June 2019
Biotechnology
Intensity Therapeutics has entered into an agreement with Merck & Co to test a combination of the firm’s lead product candidate INT230-6 together with Merck’s flagship checkpoint inhibitor, Keytruda (pembrolizumab). 26 June 2019
Biotechnology
Bucking the trend of negative news in non-alcoholic steatohepatitis (NASH), France-based biotech Genfit has agreed a major licensing and collaboration deal with Shanghai's Terns Pharmaceuticals. 26 June 2019
Biotechnology
Oxford Biomedica and Santen Pharmaceutical have entered into an R&D collaboration and option and licence agreement to research and develop gene therapy products for the treatment of an inherited retinal disease. 26 June 2019
Biotechnology
A new biopharma research company, Frontier Medicines, has launched in California USA, via a Series A Preferred Stock financing round of $67 million. 26 June 2019
Biotechnology
Oncolytic adenovirus company Theolytics has exited stealth mode to announce the appointment of a chairman of the board. 25 June 2019
Biotechnology
Asian healthcare platform Novena Global Lifecare Group is to join with two other groups to create the Sino-Singapore Healthcare Fund with a target size of $150 million. 25 June 2019
Biotechnology
Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe from USA-based Dermira. 25 June 2019
Biotechnology
French biotech ERYTECH Pharma has entered into a collaboration with privately-held US cell therapy company SQZ Biotechnologies (SQZ) to advance red blood cell (RBC)-based therapeutics for immune modulation. 25 June 2019
Biotechnology
Swiss drugmaker Santhera Pharmaceuticals has had its marketing authorization application (MAA) accepted for Puldysa (idebenone) to treat respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) who are not using glucocorticoids. 25 June 2019
Biotechnology
UK-based C4X Discovery Holdings saw its shares climb 4.55% to 52.80 pence, after announcing a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. 25 June 2019
Biotechnology
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
Biotechnology
The US Food and Drug Administration has issued a priority review voucher (PRV) to rare disease specialist AveXis, part of Swiss pharma giant Novartis. 25 June 2019
Biotechnology
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze